Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

NCT00275821 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

353

Enrollment

INDUSTRY

Sponsor class

Conditions

Age Related Macular Degeneration

Interventions

DRUG: Ranibizumab 0.3 mg - 3 times monthly, then quarterly
DRUG: Ranibizumab 0.5 mg - 3 times monthly, then quarterly
DRUG: Ranibizumab 0.3 mg monthly

Sponsor

Novartis